Table 2.
PCMH Recognition | ||
---|---|---|
Yes (N = 539) | No (N = 548) | |
Clinical performance measures | 2012 | 2012 |
% Adult receiving weight screening** | 47.77 (0.89) | 44.05 (0.98) |
% Aspirin therapy | 70.13 (0.87) | 70.79 (0.91) |
% Asthma patients receiving pharmacologic therapy* | 75.66 (0.91) | 72.61 (1.09) |
% Colorectal cancer screening | 27.99 (0.8) | 27.18 (0.86) |
% Child immunization | 38.72 (1.11) | 39.32 (1.32) |
% Child weight assessment* | 42.78 (1.1) | 39.45 (1.14) |
% Diabetes control (HBA1c<7)** | 41.19 (0.38) | 39.24 (0.49) |
% Diabetes control (HBA1c<8)*** | 59.68 (0.46) | 57.13 (0.58) |
% Diabetes control (HBA1c<9)*** | 71.17 (0.47) | 68.43 (0.6) |
% Hypertension control* | 63.93 (0.44) | 62.49 (0.48) |
% LBW | 7.18 (0.2) | 7.12 (0.23) |
% Lipid therapy | 75.59 (0.77) | 73.95 (0.85) |
% Pap test*** | 54.59 (0.73) | 50.51 (0.83) |
% Prenatal care*** | 72.58 (0.7) | 68.67 (0.89) |
% Tobacco assessment*** | 87.64 (0.69) | 83.85 (0.81) |
% Tobacco cessation intervention** | 59.9 (1.05) | 55.51 (1.14) |
*p < .05, **p < .01, ***p < .001, based on paired t‐test for PCMH vs. non‐PCMH centers within the same year.